Humanin is a novel neuroprotective agent against stroke.

Xingshun Xu, Chu C Chua, Jinping Gao, Ronald C Hamdy, Balvin H L Chua
Author Information
  1. Xingshun Xu: Department of Pharmacology, James H. Quillen College of Medicine, East Tennessee State University, Johnson City, TN 37614, USA.

Abstract

BACKGROUND AND PURPOSE: Humanin (HN) is a 24-amino acid peptide best known for its ability to protect neurons from damage caused by Alzheimer disease-related proteins. This study examines the neuroprotective effects of HNG (a potent form of HN) on focal cerebral ischemia/reperfusion injury in mice.
METHODS: Mice underwent middle cerebral artery occlusion for 75 minutes followed by 24-hour reperfusion. Mice were pretreated with 0.1 microg HNG (intracerebroventricularly) 30 minutes before ischemia; posttreated at 0, 2, 4, and 6 hours after ischemia; or pretreated with 1 microg HNG (intraperitoneally) 1 hour before ischemia. Neurological deficits and cerebral infarct volume were evaluated. Neuronal apoptosis and activated poly(ADP-ribose) polymerase expression were measured by TUNEL and Western blot analysis, respectively. Activated ERKs were examined by Western blot analysis.
RESULTS: Pretreatment with 0.1 microg HNG (intracerebroventricularly) 30 minutes before ischemia reduced cerebral infarct volume from 56.2+/-3.0% to 26.1+/-1.4% (P<0.01). HNG posttreatment after 4 hours of reperfusion reduced cerebral infarct volume to 45.6+/-2.6% (P<0.05). Pretreatment with 1 microg HNG (intraperitoneally) 1 hour before ischemia or posttreatment after 2 hours of reperfusion reduced cerebral infarct volume significantly. HNG also significantly improved neurological function and inhibited both neuronal apoptosis as well as poly(ADP-ribose) polymerase activation. A significant decrease of phospho-ERK was observed in mice treated with HNG, whereas phospho-JNK and phospho-p38 levels were not altered.
CONCLUSIONS: Our results demonstrate that HNG protects against cerebral ischemia/reperfusion injury in mice. HNG offers neuroprotection in vivo at least in part by inhibiting ERK activation. These findings suggest a potential therapeutic role for HNG in the treatment of stroke.

MeSH Term

Animals
Apoptosis
Blood-Brain Barrier
Brain Ischemia
Drug Evaluation, Preclinical
Enzyme Activation
Infarction, Middle Cerebral Artery
Injections, Intraventricular
JNK Mitogen-Activated Protein Kinases
Male
Mice
Mitogen-Activated Protein Kinase 1
Mitogen-Activated Protein Kinase 3
Movement Disorders
Neurons
Neuroprotective Agents
Peptides
Random Allocation
Reperfusion Injury
Stroke
p38 Mitogen-Activated Protein Kinases

Chemicals

Gly(14)-Humanin
Neuroprotective Agents
Peptides
JNK Mitogen-Activated Protein Kinases
Mitogen-Activated Protein Kinase 1
Mitogen-Activated Protein Kinase 3
p38 Mitogen-Activated Protein Kinases

Word Cloud

Created with Highcharts 10.0.0HNGcerebral1ischemiamicroginfarctvolumemiceminutesreperfusion0hoursreducedHumaninHNneuroprotectiveischemia/reperfusioninjuryMicepretreatedintracerebroventricularly3024intraperitoneallyhourapoptosispolyADP-ribosepolymeraseWesternblotanalysisPretreatmentP<0posttreatmentsignificantlyactivationstrokeBACKGROUNDANDPURPOSE:24-aminoacidpeptidebestknownabilityprotectneuronsdamagecausedAlzheimerdisease-relatedproteinsstudyexamineseffectspotentformfocalMETHODS:underwentmiddlearteryocclusion75followed24-hourposttreated6NeurologicaldeficitsevaluatedNeuronalactivatedexpressionmeasuredTUNELrespectivelyActivatedERKsexaminedRESULTS:562+/-30%261+/-14%01456+/-26%05alsoimprovedneurologicalfunctioninhibitedneuronalwellsignificantdecreasephospho-ERKobservedtreatedwhereasphospho-JNKphospho-p38levelsalteredCONCLUSIONS:resultsdemonstrateprotectsoffersneuroprotectionvivoleastpartinhibitingERKfindingssuggestpotentialtherapeuticroletreatmentnovelagent

Similar Articles

Cited By